Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07067788

B.Brilliant Revelation Comparision Study

This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Pennsylvania Hospital, Center for Breast Imaging

Philadelphia, Pennsylvania, 19107, United States

Location status: Recruiting

Location contact

Brian S. Englander, MD

PRINCIPAL_INVESTIGATOR

Elizabeth McDonald, MD, PHD

SUB_INVESTIGATOR

Jessica Nunez

CONTACT

[email protected]

215-829-3712

Namaijah Faison, MPH

CONTACT

[email protected]

267-432-5000

About this study

Women scheduled at Pennsylvania Hospital to undergo a standard of care diagnostic imaging exam after having had a standard of care screening exam performed on either the MAMMOMAT B.brilliant (NDBT) or the MAMMOMAT Revelation (DBT) mammography system with findings consistent with suspicious calcifications or calcifications associated with other lesion types will be eligible and approached to enroll in the study. Participants must be ≥ 18 years of age. Up to 125 evaluable participants will be enrolled.

Eligible and consented participants enrolled in the study will receive standard of care diagnostic imaging on the same mammography system as the screening exam and receive two additional research images on the other mammography system.

Both mammographic units are FDA approved and located at Pennsylvania Hospital.

The research scans required for this study will include either 5-8 seconds or 25 seconds of compression in two views (MLO & CC) of the affected breast (breast with suspicious calcifications at screening). Data will be collected to evaluate image quality regarding the visibility of calcifications. This study seeks to evaluate MAMMOMAT B.brilliant, which has decreased acquisition time and increased conspicuity of calcifications, as a replacement to standard wide-angle imaging as on the MAMMOMAT Revelation.

This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants will be ≥ 18 years of age.
  • Participants will be females (sex assigned at birth).
  • Participants will be presenting for clinical diagnostic mammography with suspicious calcifications or calcifications associated with other lesion types
  • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion criteria

  • Females who are breast-feeding will not be eligible for this study
  • Pregnant women will not be included. All females of childbearing potential must attest that they are not pregnant.
  • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
  • Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

Treatment and study plan

Breast Imaging

Diagnostic Test

Intervention using an FDA-approved mammogram machine.

Primary outcomes

  1. Comparison of two Siemen System B.brillant and the Revelation

    Time frame: From enrollment to the end of study at 18 months

    • To assess whether the MAMMOMAT B.brilliant, a Novel Wide-Angle Digital Breast Tomosynthesis (NDBT) System, leads to better visualization of calcifications compared to the MAMMOMAT Revelation, a standard wide-angle Digital Breast Tomosynthesis (DBT) System, including the assessment of calcifications on synthetic images for both tomosynthesis scans.

Secondary outcomes

  1. Accuracy of Calcifications and patient survey

    Time frame: From enrollment to the end of study at 18 months

    • To evaluate the accuracy of B.brilliant for predicting the number of calcifications and extent of the calcification cluster(s) and morphology compared to standard wide-angle DBT (including synthetic images for both) with diagnostic magnification views as the gold standard.
  2. Assessing the pain on two standard mammogram scanners

    Time frame: From enrollment to the end of study at 18 months

    To assess whether subjects imaged with B.brilliant and standard wide-angle DBT perceive any difference in ease of exam or pain. We are using a numerical pain scale, a 0 to 5 point scale. 0 no pain and 5 severe pain

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica Nunez Project Manager

CONTACT

[email protected]

215-829-3712

Namaijah Faison Clinical Research Coordinator

CONTACT

[email protected]

215-432-5000

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • Siemens Corporation, Corporate Technology

Registry information

Official study title

A Clinical Comparison of Siemens Mammomat B.Brilliant , A Novel Wide-Angel Digitial Breast Tomosynthesis System With Siemens Mammomat Revelation , A Standard Wide-Angle Digital Breast Tomosynthesis System

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jul 16, 2025
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.